EV	Enfortumab vedotin
mUC	Metastatic urothelial carcinoma
CI	Confidence Interval
EV + P	Enfortumab vedotin in combination with pembrolizumab
ADC	Antibody drug conjugate
MMAE	Monomethyl auristatin E
EMT	Epithelial–mesenchymal transition
PD-1	Programed cell death-1
ICD	Immunogenic cell death
DAMPs	Damage-associated molecular patterns
OS	Overall Survival
PFS	Progression free survival
ORR	Overall response rate
MIBC	Muscle invasive bladder cancer
pCR	Pathologic complete response
pDS	Pathologic downstaging
EAU	European Association of Urology
ESMO	European Society for Medical Oncology
ASCO	American Society for Clinical Oncology
NMIBC	Non-muscle invasive bladder cancer
CAB	Conditionally active biologic
BTC	Bicyclic toxin conjugate